This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beckett, M. L. Articles by Wright, G. L. Search for Related Content PubMed PubMed Citation Articles by Beckett, M. L. Articles by Wright, G. L., Jr.

Prostate-specific Membrane Antigen Levels in Sera from Healthy Men and Patients with Benign Prostate Hyperplasia or Prostate Cancer¹

Departments of Microbiology and Molecular Cell Biology [M. L. B., L. H. C., A. V., G. L. W.] and Urology [P. F. S., G. L. W.] and the Virginia Prostate Center [M. L. B., L. H. C., A. V., P. F. S., G. L. W.], Eastern Virginia Medical School, and Sentara Cancer Institute [M. L. B., L. H. C., A. V., P. F. S., G. L. W.], Norfolk, Virginia 23501

Prostate-specific membrane antigen (PSMA) serum levels have been proposed to be of prognostic significance in patients with advanced prostate disease. The objective of the present study was to confirm PSMA serum expression by Western blot techniques, to determine whether such data could assist in the differentiation of benign from malignant prostatic disease, and to determine the suitability of serum PSMA measurements in predicting recurrent or progressive prostate malignancies. We measured PSMA, a transmembrane glycoprotein identified in prostate epithelial cells, in the sera of 236 normal individuals and cancer patients by Western blot analysis. Within the normal male population, PSMA levels increase with age and were found to be significantly elevated in subjects more than 50 years of age when compared to those of younger men. We did not confirm previous reports that serum PSMA measurements could distinguish late-stage prostate carcinoma from early-stage prostate carcinoma, nor did we find PSMA to be more effective than prostate-specific antigen in monitoring prostate cancer patient prognosis. Furthermore, we found elevated serum PSMA in healthy females, and, similar to the healthy male population, the levels increased with age, with the highest levels found in the sera from breast cancer patients. These latter observations further support that PSMA is not a specific biomarker for prostate cancer and that a variety of normal and diseased tissue may contribute to the serum levels of PSMA.

This article has been cited by other articles:

				J. V. Tricoli, M. Schoenfeldt, and B. A. Conley Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers Clin. Cancer Res., June 15, 2004; 10(12): 3943 - 3953. [Abstract] [Full Text] [PDF]

				S Jain, A G Bhojwani, and J K Mellon Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers Postgrad. Med. J., November 1, 2002; 78(925): 646 - 650. [Abstract] [Full Text] [PDF]

				D. Karan, D. L. Kelly, A. Rizzino, M.-F. Lin, and S. K. Batra Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells Carcinogenesis, June 1, 2002; 23(6): 967 - 976. [Abstract] [Full Text] [PDF]

				Z. Xiao, B.-L. Adam, L. H. Cazares, M. A. Clements, J. W. Davis, P. F. Schellhammer, E. A. Dalmasso, and G. L. Wright Jr. Quantitation of Serum Prostate-specific Membrane Antigen by a Novel Protein Biochip Immunoassay Discriminates Benign from Malignant Prostate Disease Cancer Res., August 1, 2001; 61(16): 6029 - 6033. [Abstract] [Full Text] [PDF]